Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal Cancer
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
In this study, patients will receive either pemetrexed plus irinotecan or 5-fluorouracil
(5-FU), leucovorin, and irinotecan.
The purposes of this study are to determine:
- How pemetrexed plus irinotecan compares with 5-FU, leucovorin, and irinotecan in terms
of efficacy.
- The safety of pemetrexed plus irinotecan and any side effects that might be associated
with it as compared with 5-FU, leucovorin, and irinotecan.
- Whether pemetrexed can help patients with colorectal cancer.